Global Lipid Profile Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Lipid Profile Market Overview

The Lipid Profile Market was valued at USD 845.85 Million in 2025 and is projected to reach USD 1348.56 Million by 2033, growing at a CAGR of 6.00% from 2026 to 2033. The Lipid Profile Market is experiencing consistent growth driven by rising prevalence of cardiovascular diseases, increasing awareness regarding preventive healthcare, growing adoption of routine health screening programs, and advancements in diagnostic technologies. The expanding geriatric population, rising incidence of lifestyle-related disorders such as obesity and diabetes, and increasing focus on early detection of lipid abnormalities are accelerating demand for lipid profile testing worldwide.

The growing burden of cardiovascular risk factors, combined with increasing healthcare initiatives for disease prevention and monitoring, is encouraging hospitals, diagnostic laboratories, and healthcare providers to adopt advanced lipid testing solutions. Automated analyzers, point-of-care testing devices, and advanced laboratory technologies are improving testing accuracy, efficiency, and accessibility across developed and emerging markets. In addition, increasing investments in healthcare infrastructure, rising availability of diagnostic services, and growing adoption of personalized healthcare approaches are further supporting the expansion of the Lipid Profile Market.

Key Market Trends & Insights

• North America dominated the Lipid Profile Market with the largest revenue share of 38.6% in 2025, supported by the high prevalence of cardiovascular diseases, strong adoption of preventive healthcare screening programs, advanced diagnostic laboratory infrastructure, and increasing demand for routine cholesterol and lipid testing. The region’s growth is further strengthened by the presence of leading diagnostic companies, widespread insurance coverage, and increasing awareness regarding early detection and management of dyslipidemia.
• The Statins segment dominated the market with a 52.5% share in 2025, due to their established role as the first-line treatment for lowering LDL cholesterol and reducing cardiovascular disease risk.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.3% from 2026 to 2033, fueled by rising incidence of cardiovascular diseases, growing healthcare expenditure, expanding diagnostic laboratory networks, and increasing awareness of preventive health screening. Countries such as India, China, and Japan are witnessing rapid adoption of lipid testing due to aging populations, lifestyle-related disorders, and improving access to advanced diagnostic services.
• The Automated Lipid Profile Analyzers segment is projected to be the fastest-growing technology category, registering a CAGR of approximately 8.7%, driven by increasing laboratory automation, demand for high-throughput testing, improved diagnostic accuracy, and reduced turnaround time. Hospitals and diagnostic centers are increasingly adopting automated systems to efficiently manage growing volumes of lipid screening tests.
• The Cardiovascular Disease Risk Assessment application segment dominated the market with approximately 46.5% revenue share in 2025, supported by the increasing global burden of heart disease, rising demand for early risk identification, and growing integration of lipid profile testing into preventive healthcare programs. Healthcare providers are increasingly using lipid biomarkers to guide treatment decisions and monitor cardiovascular health.
• Hospital Laboratories accounted for the largest end-user share of in 2025, driven by high patient volumes, availability of advanced diagnostic infrastructure, and the increasing use of lipid testing for inpatient and outpatient cardiovascular risk management. The expansion of hospital-based diagnostic services continues to support market growth.

Market Size & Forecast

• Global Market Value (2025): USD 845.85 Million
• Expected Market Value (2033): USD 1348.56 Million
• Forecast CAGR (2026–2033): 6.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Lipid Profile Market Segmentation

Lipid Profile Market Trends

Trend: Increasing Adoption of Lipid Testing for Preventive Cardiovascular Healthcare

The Lipid Profile Market is witnessing a strong shift toward preventive healthcare, with healthcare providers increasingly emphasizing early detection and continuous monitoring of cardiovascular risk factors. Lipid profile testing, including measurements of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, is becoming a routine diagnostic procedure due to the rising burden of cardiovascular diseases, obesity, diabetes, and lifestyle-related metabolic disorders. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, accounting for approximately 17.9 million deaths annually, increasing the importance of regular cholesterol screening and risk assessment. Hospitals, diagnostic laboratories, and preventive healthcare programs are expanding lipid testing adoption to identify high-risk individuals earlier and support timely intervention. The trend is further supported by increasing demand for automated lipid analyzers and point-of-care testing solutions that provide faster results with improved accuracy. Diagnostic laboratories are increasingly adopting high-throughput platforms to manage growing screening volumes, while healthcare systems are integrating lipid testing into routine wellness programs and chronic disease management pathways.

Lipid Profile Market Dynamics

Key Market Driver: Rising Prevalence of Cardiovascular Diseases and Increasing Demand for Early Risk Detection

The increasing global prevalence of cardiovascular disorders is a major factor driving growth in the Lipid Profile market. Elevated cholesterol levels and abnormal lipid patterns are recognized as major contributors to atherosclerosis, coronary artery disease, and stroke, encouraging greater adoption of lipid screening across hospitals, diagnostic centers, and primary healthcare facilities. The growing aging population is significantly contributing to market expansion, as older adults have a higher risk of developing dyslipidemia and cardiovascular complications. In addition, rising rates of obesity, diabetes, sedentary lifestyles, and unhealthy dietary patterns are increasing the need for regular lipid monitoring. North America continues to represent a major market due to advanced diagnostic infrastructure, strong preventive healthcare practices, and widespread cardiovascular screening initiatives. Meanwhile, emerging markets such as India and China are experiencing rapid growth due to expanding healthcare access, increasing diagnostic awareness, and rising investments in laboratory infrastructure. The adoption of advanced diagnostic technologies is also accelerating market growth. Automated lipid analyzers, laboratory information systems (LIS), and integrated diagnostic platforms are enabling laboratories to improve testing efficiency, reduce processing time, and handle increasing patient volumes.

Key Restraint/Challenge: Limited Access to Advanced Lipid Testing and Cost Constraints in Emerging Markets

A key challenge in the Lipid Profile Market is the uneven availability of advanced diagnostic infrastructure, particularly across low- and middle-income countries. While developed markets have widespread access to automated analyzers and routine lipid screening programs, many emerging regions continue to face limitations related to healthcare infrastructure, trained laboratory professionals, and affordability. The cost associated with advanced automated lipid analyzers, reagent kits, maintenance, and calibration requirements can restrict adoption among smaller diagnostic laboratories and rural healthcare facilities. In addition, limited awareness regarding preventive cardiovascular screening in certain populations reduces the frequency of routine lipid testing. For instance, healthcare systems in several developing economies are still transitioning from reactive disease treatment models toward preventive screening approaches, creating a gap in early cardiovascular risk detection. Addressing affordability, improving diagnostic access, and expanding public health screening initiatives remain important factors for broader market penetration.

Key Market Opportunity: Integration of Automation, Digital Health, and AI-Based Cardiovascular Risk Assessment

The integration of automation, artificial intelligence (AI), and digital health technologies presents significant growth opportunities for the Lipid Profile market. AI-enabled diagnostic platforms are increasingly being explored to analyze patient data, identify cardiovascular risk patterns, and support personalized disease management strategies. Advanced laboratory automation is enabling faster and more standardized lipid testing by reducing manual intervention and improving workflow efficiency. Diagnostic companies are increasingly developing integrated systems that combine lipid testing with broader metabolic and cardiovascular health assessments. The expansion of point-of-care lipid testing solutions also creates opportunities for decentralized healthcare delivery. These systems allow rapid cholesterol testing in primary care clinics, pharmacies, and community healthcare settings, improving access to early screening. In addition, increasing adoption of electronic health records (EHRs) and digital patient monitoring platforms is enabling healthcare providers to track lipid trends over time and support preventive care strategies. Growing healthcare investments in Asia-Pacific, Latin America, and the Middle East are expected to further accelerate adoption of advanced lipid testing technologies and expand market growth opportunities through 2033.

Lipid Profile Market Scope

The Lipid Profile market is segmented on the basis of type, indication, technology, distribution channel, medication, and end user.

• By Type

On the basis of type, the Lipid Profile Market is segmented into Total Cholesterol, LDL (Low-Density Lipoprotein), HDL (High-Density Lipoprotein), and Triglycerides. The LDL (Low-Density Lipoprotein) segment dominated the market with a 34.6% share in 2025, owing to its importance as a primary biomarker for cardiovascular disease risk assessment and cholesterol management. LDL testing is widely performed across hospitals, diagnostic laboratories, and preventive healthcare facilities due to its role in identifying patients at risk of atherosclerosis and heart-related complications. The increasing prevalence of cardiovascular diseases, obesity, diabetes, and sedentary lifestyles is driving the demand for LDL monitoring worldwide. Growing awareness regarding preventive healthcare and routine health screening programs is further supporting segment growth. In addition, healthcare providers are increasingly recommending LDL testing as part of regular cardiovascular risk evaluation. The availability of automated laboratory analyzers and advanced diagnostic platforms is improving testing efficiency and accuracy. Furthermore, increasing investments in healthcare infrastructure and expansion of diagnostic services in emerging economies are reinforcing the leading position of this segment.

The Triglycerides segment is expected to witness the fastest CAGR of 7.2% from 2026 to 2033, driven by the increasing prevalence of metabolic disorders, obesity, diabetes, and cardiovascular risk factors. Elevated triglyceride levels are becoming a major health concern, increasing the need for regular lipid monitoring and early intervention. The growing focus on preventive healthcare and lifestyle-related disease management is accelerating demand for triglyceride testing. In addition, increasing adoption of comprehensive lipid panels that include triglyceride measurement is supporting market expansion. Technological advancements in automated diagnostic systems are improving accessibility and reducing testing time. Rising awareness among patients regarding cholesterol and lipid management is further contributing to segment growth. Furthermore, increasing healthcare screening initiatives and expanding diagnostic facilities across developing regions are expected to create significant growth opportunities.

• By Indication

On the basis of indication, the Lipid Profile Market is segmented into High Blood Pressure, Genetic Disease, Diabetes, Obesity, and Others. The Diabetes segment dominated the market with a 31.8% share in 2025, due to the strong relationship between diabetes and lipid abnormalities, including elevated LDL cholesterol and triglyceride levels. Patients with diabetes are at increased risk of cardiovascular complications, resulting in higher demand for regular lipid profile testing. Growing prevalence of diabetes globally, along with increasing awareness regarding diabetes management, is supporting segment growth. Healthcare providers increasingly recommend lipid monitoring as part of routine diabetes care to reduce cardiovascular risks. In addition, government initiatives promoting chronic disease screening are improving access to diagnostic services. The rising adoption of preventive healthcare approaches and increasing healthcare expenditure are further strengthening market expansion. Furthermore, the integration of lipid testing into diabetes management programs is reinforcing the dominance of this segment.

The Obesity segment is projected to register the fastest CAGR of 7.5% from 2026 to 2033, driven by the increasing global burden of obesity and associated metabolic disorders. Obesity is strongly linked with abnormal cholesterol levels, insulin resistance, and increased cardiovascular risk, creating significant demand for lipid profile testing. Rising awareness regarding obesity-related health complications is encouraging individuals to undergo regular screening. The expansion of weight management programs and preventive healthcare initiatives is further supporting segment growth. In addition, healthcare systems are increasingly focusing on early detection of metabolic abnormalities among obese populations. Growing adoption of personalized health monitoring solutions and lifestyle management programs is expected to accelerate demand. Furthermore, increasing incidence of obesity among younger populations is creating long-term opportunities for lipid testing services.

• By Technology

On the basis of technology, the Lipid Profile Market is segmented into PCR Based, ELISA, and Others. The ELISA segment dominated the market with a 42.3% share in 2025, owing to its widespread application in diagnostic laboratories due to high accuracy, reliability, and cost-effectiveness. ELISA-based technologies are extensively used for biomarker detection and clinical diagnostics, making them a preferred option across healthcare facilities. Increasing demand for precise laboratory testing and rising adoption of advanced diagnostic platforms are supporting segment growth. The technology provides efficient processing of large patient volumes, which is important for hospitals and diagnostic centers. In addition, continuous improvements in assay technologies are enhancing testing performance and reliability. Growing investments in healthcare diagnostics and expansion of laboratory networks are further strengthening adoption. Furthermore, the availability of established ELISA-based testing infrastructure is maintaining the leading position of this segment.

The PCR Based segment is expected to witness the fastest CAGR of 8.1% from 2026 to 2033, driven by increasing adoption of advanced molecular diagnostic technologies and growing interest in personalized healthcare. PCR-based approaches are gaining importance due to their ability to provide detailed molecular insights related to disease risk and genetic factors. Increasing research activities focused on lipid metabolism and cardiovascular risk assessment are supporting segment growth. The integration of molecular diagnostics with precision medicine approaches is creating new opportunities for PCR-based testing. In addition, technological advancements are improving testing accuracy, speed, and accessibility. Rising healthcare investments and increasing adoption of advanced diagnostics in developed and emerging markets are further accelerating growth.

• By Distribution Channel

On the basis of distribution channel, the Lipid Profile Market is segmented into Online, Retail, and Direct Tender. The Direct Tender segment dominated the market with a 46.7% share in 2025, due to bulk procurement of diagnostic products by hospitals, laboratories, and healthcare institutions. Direct tender channels provide cost benefits, reliable supply arrangements, and efficient procurement for large healthcare organizations. The segment benefits from increasing expansion of healthcare facilities and diagnostic networks globally. Government healthcare programs and institutional purchasing agreements are also contributing to segment dominance. In addition, diagnostic laboratories prefer direct procurement channels to maintain consistent availability of testing supplies. Growing demand for large-scale screening programs is further supporting this segment. Furthermore, partnerships between manufacturers and healthcare institutions are strengthening distribution efficiency.

The Online segment is expected to register the fastest CAGR of 8.4% from 2026 to 2033, driven by increasing digital healthcare adoption and growing demand for convenient diagnostic access. Online healthcare platforms are enabling consumers to access testing services more easily and efficiently. Rising adoption of home diagnostic solutions and digital health platforms is supporting segment growth. Increasing internet penetration and consumer preference for convenient healthcare services are accelerating online channel expansion. In addition, growing awareness regarding preventive health monitoring is increasing demand for online lipid testing services. The expansion of e-commerce healthcare platforms is further improving accessibility.

• By Medication

On the basis of medication, the Lipid Profile Market is segmented into Statins, Niacin, Fibrates, Zetia, and Bile Acid Sequestrants. The Statins segment dominated the market with a 52.5% share in 2025, due to their established role as the first-line treatment for lowering LDL cholesterol and reducing cardiovascular disease risk. Statins are widely prescribed because of their proven effectiveness, clinical acceptance, and long-term safety profile. Increasing prevalence of hypercholesterolemia and cardiovascular diseases is driving demand for statin-based therapies. Healthcare professionals continue to recommend statins as a major component of cholesterol management strategies. Rising awareness regarding cardiovascular prevention and increasing healthcare access are further supporting segment growth. In addition, continuous clinical studies validating statin effectiveness are strengthening adoption globally. The strong availability of generic statin medications is also contributing to market dominance.

The Fibrates segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by increasing demand for triglyceride management therapies among patients with metabolic disorders. Rising prevalence of diabetes, obesity, and mixed lipid disorders is increasing the need for alternative lipid-lowering treatments. Fibrates are gaining attention due to their effectiveness in managing elevated triglyceride levels. Increasing focus on comprehensive lipid management is supporting segment growth. Furthermore, rising physician awareness regarding combination approaches for lipid control is contributing to adoption. Expanding healthcare access in emerging markets is expected to further accelerate segment growth.

• By End User

On the basis of end user, the Lipid Profile Market is segmented into Clinics, Hospitals, Ambulatory Centers, Homecare, and Diagnostic Centers. The Diagnostic Centers segment dominated the market with a 39.4% share in 2025, due to increasing demand for routine health screening and specialized laboratory testing services. Diagnostic centers provide advanced testing infrastructure, faster results, and accessibility for large patient populations. Rising awareness regarding preventive healthcare is increasing the frequency of lipid profile testing. Expansion of diagnostic chains and healthcare networks is supporting segment growth. In addition, increasing cardiovascular disease screening programs are driving demand for diagnostic services. The availability of automated testing systems and skilled laboratory professionals further strengthens this segment.

The Homecare segment is projected to register the fastest CAGR of 9.0% from 2026 to 2033, driven by increasing demand for convenient and remote health monitoring solutions. Growing adoption of digital health technologies and patient-centered care models is supporting home-based lipid testing. Patients with chronic conditions such as diabetes and cardiovascular disorders are increasingly preferring self-monitoring solutions. Advancements in portable diagnostic devices and connected healthcare platforms are accelerating segment growth. In addition, increasing healthcare costs and demand for accessible testing options are creating opportunities for homecare lipid profile solutions.

Lipid Profile Market Regional Analysis

North America dominated the Lipid Profile Market with the largest revenue share of approximately 38.6% in 2025, supported by the high prevalence of cardiovascular diseases, strong adoption of preventive healthcare screening programs, advanced diagnostic laboratory infrastructure, and increasing demand for routine cholesterol and lipid testing. The region benefits from widespread availability of automated diagnostic systems, strong healthcare expenditure, established clinical laboratory networks, and increasing awareness regarding early detection and management of dyslipidemia. The presence of leading diagnostic companies, advanced healthcare facilities, and favorable reimbursement structures continues to strengthen market growth across the region. Increasing adoption of lipid profile testing for cardiovascular risk assessment, diabetes management, and routine wellness screening is further driving demand. In addition, growing emphasis on preventive healthcare and early intervention strategies is encouraging healthcare providers to integrate lipid testing into regular patient monitoring programs.

U.S. Lipid Profile Market Insight

The U.S. Lipid Profile market is witnessing significant growth due to the increasing burden of cardiovascular diseases, rising demand for preventive health screening, and widespread adoption of advanced diagnostic technologies. The country’s well-established healthcare infrastructure, large network of clinical laboratories, and strong presence of diagnostic companies are supporting market expansion. Growing awareness regarding cholesterol management and cardiovascular risk reduction is increasing the adoption of lipid testing across hospitals, outpatient clinics, and diagnostic centers. In addition, initiatives focused on preventive healthcare, increasing routine health check-ups, and the adoption of automated lipid analyzers are improving testing accessibility and efficiency. The integration of digital health platforms and electronic health records is further enabling continuous monitoring of lipid levels and personalized cardiovascular care.

Europe Lipid Profile Market Insight

The Europe Lipid Profile market remains a major contributor to global revenue, supported by strong healthcare systems, increasing cardiovascular disease screening initiatives, and growing adoption of advanced diagnostic solutions. The region benefits from widespread access to clinical laboratories, established preventive healthcare programs, and increasing focus on early detection of metabolic and cardiovascular disorders. Countries across Europe are witnessing rising demand for lipid profile testing due to aging populations, increasing prevalence of obesity and diabetes, and government-led cardiovascular health initiatives. The adoption of automated diagnostic platforms and laboratory modernization programs is further improving testing efficiency. Increasing emphasis on preventive medicine and regular health monitoring continues to support market growth across the region.

U.K. Lipid Profile Market Insight

The U.K. Lipid Profile market is experiencing steady growth, driven by increasing cardiovascular screening efforts, rising awareness of cholesterol management, and expansion of preventive healthcare services. The country’s healthcare system is increasingly focusing on early identification of cardiovascular risk factors, supporting higher adoption of lipid profile testing. Growing investments in diagnostic infrastructure, laboratory automation, and population health programs are contributing to market expansion. Furthermore, increasing demand for routine cholesterol monitoring among aging populations and individuals with metabolic disorders is supporting the adoption of lipid testing across hospitals, primary care centers, and diagnostic laboratories.

Germany Lipid Profile Market Insight

The Germany Lipid Profile market is expanding steadily due to its advanced healthcare infrastructure, strong diagnostic laboratory network, and increasing focus on cardiovascular disease prevention. Germany’s high healthcare expenditure and strong emphasis on preventive screening are supporting widespread adoption of lipid testing technologies. Hospitals and diagnostic laboratories are increasingly adopting automated analyzers and advanced laboratory solutions to improve testing accuracy and workflow efficiency. Rising incidence of lifestyle-related diseases, including obesity and diabetes, is further increasing demand for lipid monitoring. In addition, Germany’s strong medical technology sector and continued investments in healthcare innovation are supporting market growth.

Asia-Pacific Lipid Profile Market Insight

The Asia-Pacific Lipid Profile market is expected to be the fastest-growing regional market, registering a CAGR of approximately 8.3% from 2026 to 2033, driven by the rising incidence of cardiovascular diseases, growing healthcare expenditure, expanding diagnostic laboratory networks, and increasing awareness of preventive health screening. Countries including India, China, and Japan are witnessing rapid adoption of lipid testing due to aging populations, increasing prevalence of lifestyle-related disorders, rising healthcare access, and growing demand for early cardiovascular risk detection. The expansion of private diagnostic chains, increasing availability of automated laboratory systems, and government initiatives supporting preventive healthcare are further accelerating regional market growth

Japan Lipid Profile Market Insight

The Japan Lipid Profile market is witnessing consistent growth due to the country’s aging population, high prevalence of cardiovascular risk factors, and advanced healthcare infrastructure. Japan’s strong focus on preventive healthcare and regular health screening programs is supporting increased adoption of lipid profile testing. Hospitals and diagnostic laboratories are increasingly using automated lipid analyzers and advanced diagnostic platforms to improve efficiency and accuracy. The growing demand for routine cardiovascular monitoring among elderly populations, combined with Japan’s emphasis on early disease detection, is expected to further strengthen market growth.

China Lipid Profile Market Insight

The China Lipid Profile market is growing rapidly due to increasing cardiovascular disease prevalence, expanding healthcare infrastructure, rising diagnostic awareness, and growing investments in preventive healthcare services. The country’s large population base and increasing burden of lifestyle-related diseases are creating significant demand for cholesterol and lipid testing solutions. Growing adoption of automated laboratory systems across hospitals and diagnostic centers is improving access to lipid testing services. Government initiatives focused on strengthening healthcare infrastructure, increasing health screening programs, and improving chronic disease management are further supporting market expansion. Rising awareness regarding cardiovascular risk prevention and increasing availability of advanced diagnostic technologies are positioning China as one of the fastest-growing markets for Lipid Profile globally.

Lipid Profile Market Share

The Lipid Profile industry is primarily led by well-established companies, including:

• Moog Inc. (U.S.)
• Dallara (Italy)
• Exail (France)
• IPG Automotive GmbH (Germany)
• aiMotive (Hungary)
• VI‑grade GmbH (Germany)
• Cruden B.V. (Netherlands)
• Dynisma Ltd. (UK)
• Applied Intuition Inc. (U.S.)
• rFpro (rFpro Limited) (England)
• Siemens AG (Germany)
• Dassault Systèmes SE (France)
• MTS Systems Corporation (U.S.)
• CAE Inc. (Canada)
• NVIDIA Corporation (U.S.)
• AB Dynamics PLC (U.K.)
• Forum8 (Japan)
• Mitsubishi Precision Co., Ltd. (Japan)
• FAAC Incorporated (U.S.)
• DriveSafety (U.S.)
• Simtec Simulation Technology GmbH (Germany)
• MB Dynamics Inc. (U.S.)
• Sanlab Simulation (India)
• SimCraft (U.S.)
• CXC Simulations (U.S.)
• XPI Simulation (United Kingdom)
• Tecknotrove Simulator Systems Pvt. Ltd. (India)
• Zhejiang Kechi Intelligent Technology Co., Ltd. (China)
• Shenzhen Zhongzhi Simulation (China)
• Hindustan Simulators (India)
• DriveSimSolutions (U.S.)
• Teksim Technologies (India)
• iMVR Inc. (U.S.)
• SimXperience (U.S.)

Latest Developments in Lipid Profile Market

• In March 2022, Abbott Laboratories expanded the adoption of its Cholestech LDX™ System, a point-of-care lipid testing solution designed for rapid cardiovascular risk assessment and lipid profile analysis. The system enables healthcare professionals to measure total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides using a small blood sample with fast turnaround time. This development supports the growing demand for decentralized diagnostic solutions and reflects the increasing shift toward convenient, rapid, and accessible lipid testing in clinics, physician offices, and preventive healthcare settings
• In May 2022, Roche Diagnostics continued strengthening its clinical chemistry diagnostic portfolio through advancements in automated laboratory platforms supporting lipid profile testing. The company focused on improving laboratory efficiency, testing accuracy, and workflow automation for parameters such as cholesterol, HDL, LDL, and triglycerides. These advancements support healthcare providers in managing rising cardiovascular disease burdens and increasing demand for routine lipid screening globally
• In February 2023, Siemens Healthineers enhanced its Atellica Solution diagnostic platform capabilities by supporting advanced clinical chemistry testing workflows, including lipid profile analysis. The platform integrates automation, high-throughput processing, and digital laboratory management features, helping laboratories improve efficiency and handle increasing demand for cardiovascular screening and preventive diagnostics
• In September 2023, QuidelOrtho continued expanding its clinical diagnostics portfolio with improvements in laboratory testing solutions, including technologies supporting cardiovascular disease risk assessment and lipid-related testing. The company’s diagnostic advancements focused on improving laboratory performance, reducing testing complexity, and supporting healthcare providers with faster and more reliable diagnostic results
• In April 2024, Abbott Laboratories introduced advancements in its diagnostic solutions portfolio aimed at improving access to cardiovascular health testing, including lipid monitoring applications. The company continued focusing on point-of-care and laboratory diagnostic innovations to support early detection, monitoring, and management of cardiovascular risk factors associated with abnormal lipid levels
• In July 2024, HORIBA Medical expanded its clinical chemistry analyzer portfolio with enhanced diagnostic capabilities supporting routine biochemical testing, including lipid profile parameters. The development focused on improving testing efficiency, reliability, and accessibility for hospitals and diagnostic laboratories, supporting the growing need for cardiovascular screening solutions
• In November 2024, Roche Diagnostics strengthened its diagnostics ecosystem through continued development of automated clinical chemistry platforms supporting comprehensive lipid testing. These advancements enabled laboratories to improve workflow automation, testing consistency, and patient monitoring capabilities as demand increased for preventive cardiovascular healthcare solutions
• In March 2025, Mindray Bio-Medical Electronics continued expanding its in-vitro diagnostics portfolio with improvements in automated biochemistry analyzers supporting lipid profile testing. The company’s focus on automation, high-throughput testing, and cost-effective diagnostic solutions supported increasing adoption among hospitals and laboratories, particularly in emerging healthcare markets
• In June 2025, Thermo Fisher Scientific advanced its clinical diagnostics capabilities through continued innovation in laboratory testing solutions, supporting the growing demand for accurate lipid and cardiovascular risk assessment. The company’s developments focused on improving diagnostic efficiency, automation, and accessibility as healthcare systems increasingly prioritize early disease detection and preventive monitoring
• In August 2025, global diagnostic manufacturers increasingly integrated digital health technologies, automation, and data-driven analytics into lipid testing platforms to improve cardiovascular risk management. These developments supported the transition toward personalized healthcare by enabling more efficient monitoring of cholesterol abnormalities and improving clinical decision-making for patients at risk of cardiovascular diseases

SKU-53767